Animal cells and systems

  • 제7권3호
  • /
  • Pages.249-253
  • /
  • 2003
  • /
  • 1976-8354(pISSN)
  • /
  • 2151-2485(eISSN)
한국통합생물학회 (The Korean Society for Integrative Biology)
권호 표지

Genetic Polymorphisms of t-PA and PAI-1 Genes in the Korean Population

  • 발행 : 2003.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Abnormalities in fibrinolysis system is associated with risk of hypertension. In this report, the Alu repeat insertion/deletion (I/D) polymorphism of tissue plasminogen activator (t-PA) and the Hind III RFLP of plasminogen activator inhibitor-1 (PAI-1) genes were investigated in 115 normotensives and 83 patients with hypertension, and their association with anthropometrical data and plasma biochemical parameters were analyzed. There were no significant differences in the gene frequencies of the two candidate genes between normotensives and hypertensives, respectively. Our results indicate lack of associations between the two polymorph isms in t-PA and PAI-1 genes and risk of hypertension in the population under study. However, the Hind III RFLP of PAI-1 gene was significantly associated with plasma glucose level, suggesting its role in glucose metabolism. It needs to be tested whether this RFLP of PAI-1 gene is associated with insulin resistance syndrome or non-insulin dependent diabetes mellitus (NIDDM) in the Korean population.

키워드

참고문헌

  1. Andreasen PA, Georg B, Lund LR, Riccio A, and Stacey SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19 https://doi.org/10.1016/0303-7207(90)90164-4
  2. Benza RL, Grenett HE, Li XL, Reeder VC, Brown SL, Go RCP, Hanson KA, Perry GJ, Holman WL, McGiffin DC, Kirk KA, and Booyse FM (1998) Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease. Thromb Thrombol 5: 143-150 https://doi.org/10.1023/A:1008882113177
  3. Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemost 43: 77-89
  4. Dawson SJ, Hamsten A, Wiman B, Henney A, and Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11: 183-190 https://doi.org/10.1161/01.ATV.11.1.183
  5. Falk G, Almqvist A, Nordenhem A, Svensson H, and Wiman B (1995) Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 9: 170-174 https://doi.org/10.1016/S0268-9499(95)80007-7
  6. Fridewald WT, Levy Rl, and Friedrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18: 499-502
  7. Grenett HE, Khan N, Jiang W, and Booyse F (2000) Identification of the Hind III polymorphic site in the PAI-1 gene: analysis of the PAI-1 Hind III polymorphism by PCR. Genet Test 4: 65-68 https://doi.org/10.1089/109065700316507
  8. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, and Juhan-Vague (1997) Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI-1 activity, and triglyceride levels in a healthy population. Artheroscler Thromb Vasc Biol 17: 851-858 https://doi.org/10.1161/01.ATV.17.5.851
  9. Jeng JR, Harn HJ, Yueh KC, Jeng CY, and Shieh SM (1998) Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension. Am J Hypertens 11: 235-239 https://doi.org/10.1016/S0895-7061(97)00476-7
  10. Jeng JR, Sheu WHH, Jeng CY, Huang SH, and Shieh SM (1996) Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 9: 484-490 https://doi.org/10.1016/0895-7061(95)00442-4
  11. Kang BY, Kim KT, Eo HS, Lee KH, Hong SS, Shin JH, and Lee CC (2000) Association between genetic variation of the insulin receptor gene and essential hypertension in the Korean population. Korean J Biol Sci 4: 87-90 https://doi.org/10.1080/12265071.2000.9647528
  12. Kim HS, Hwang KY, Chung IK, Park SH, Lee MH, Kim SJ, and Hong SY (2003) Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding. J Korean Med Sci 18: 58-64 https://doi.org/10.3346/jkms.2003.18.1.58
  13. Kim JQ, Song JH, Park YB, and Hong SS (1998) Molecular basis of coronary heart disease. J Korean Med Sci 13: 1-15
  14. Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, and Douglas R (1987) Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84: 8548-8552 https://doi.org/10.1073/pnas.84.23.8548
  15. Kooistra T, Bosma PJ, Tors HAM, van den Berg AP, Meyer P, and Princen HMG (1989) Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocyte. Thromb Haemost 62: 723-728
  16. Lander ES and Schork NJ (1994) Genetic dissection of complex traits. Science 265: 2037-2048
  17. Landin K, Tengborn L, and Smith U (1990) Elevated fibrinogen and plasminogen activator inhibitor-1 (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227: 273-278 https://doi.org/10.1111/j.1365-2796.1990.tb00157.x
  18. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, and Lalouel J-M, A. (1992) Chimaeric 11 ${\beta}-hydroxylase/aldosterone$ synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262-265 https://doi.org/10.1038/355262a0
  19. Loskutoff DJ (1991) Regulation of PAI-1 gene expression. Fibrinolysis 5: 197-206 https://doi.org/10.1016/0268-9499(91)90001-K
  20. Luft FC (1999) Bad genes, good people, association, linkage, longevity and the prevention of cardiovascular disease. Clin Exp Pharmacol Physiol 26: 576-579 https://doi.org/10.1046/j.1440-1681.1999.03080.x
  21. Mansfield MW, Stickland MH, and Grant PJ (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74: 842-847
  22. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, Knowler WC, and Grant PJ (1996) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 39: 1512-1518 https://doi.org/10.1007/s001250050606
  23. Molnar-Gabor E, Endreffy E, and Rozsasi A (2000) HLA-DRB1, -DQA1, and DQB1 genotypes in patients with nasal polyposis. Laryngoscope 110: 422-425 https://doi.org/10.1097/00005537-200003000-00017
  24. Mune T, Rogerson FM, Nikkila H, Agarwal AK, and White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10: 394-399 https://doi.org/10.1038/ng0895-394
  25. Novick GE, Novick CC, Yunis J, Yunis E, de Mayolo PA, Scheer WD, Deninger PL, Stoneking M, York DS, Batzer MA, and Herrera RJ (1998) Polymorphic Alu insertions and the Asian origin of native American populations. Hum Biol 70: 23-39
  26. Ny T, Sawdey M, Lawrence D, Millan JL, and Loskutoff DJ (1986) Cloning and sequencing of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 83: 6776-6780 https://doi.org/10.1073/pnas.83.18.6776
  27. Orita M, Iwahana H, Kanazawa H, Hayashi K, and Sekiya T (1989a) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770 https://doi.org/10.1073/pnas.86.8.2766
  28. Orita M, Suzuki T, Sekiya T, and Hayashi K (1989b) Rapid and sensitive detection of point mutations and genetic polymorphisms using polymerase chain reaction. Genomics 5: 874-879 https://doi.org/10.1016/0888-7543(89)90129-8
  29. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, and Findling JW (1994) Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79: 407-414 https://doi.org/10.1016/0092-8674(94)90250-X
  30. Song J, Yoon YM, Jung HJ, Hong SH, Park H, and Kim JQ (2000) Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII arg353${\rightarrow}$Gln polymorphism in Korean patients with coronary artery disease. J Korean Med Sci 15: 146-152 https://doi.org/10.3346/jkms.2000.15.2.146
  31. Teger-Nilsson AC, Larsson T, Hjemdahl P, and Olsson G (1991) Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Circulation 84 Suppl VI: VI-72-VI-77
  32. Tishkoff SA, Ruano G, Kidd JR, and Kidd KK (1996) Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Hum Genet 97: 759-764 https://doi.org/10.1007/s004390050133
  33. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, and de Knijff P (1995) Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis. Thromb Haemost 74: 1202
  34. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PTVM, Hofman A, Kluft C, and Grobbee DE (1997) Tissue plasminogen activator and risk of myocardial infarction. Circulation 95: 2623-2627 https://doi.org/10.1161/01.CIR.95.12.2623
  35. Wang B, Zhou X, Dang A, Liu G, and He R (2002) Alu-repeat polymorphism in the gene coding for tissue-plasminogen activator and the risk of hypertension in a Chinese Han population. Hypertens Res 25: 949-953 https://doi.org/10.1291/hypres.25.949
  36. Wiman B and Hamsten A (1990) The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb Hemost 16: 207-216 https://doi.org/10.1055/s-2007-1002671
  37. Yang-Feng TL, Opdenakker G, Volckaert G, and Francke U (1986) Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder. Am J Hum Genet 39: 79-87